For those looking for info re Hydrazine Sulfate, hope the attached helps.
Diana
---------------------
Forwarded message:
From: LINHILLIS@aol.com
Sender: owner-mol-cancer@lists.meds.com
Reply-to: mol-cancer@lists.meds.com
To: mol-cancer@lists.meds.com
Date: 97-10-22 03:04:31 EST
There have been a lot of questions re Hydrazine Sulfate recently and thought
this might have interest for many of you. You can also find Syracuse Univ
and Dr Gold sites on internet.
Diana
---------------------
Forwarded message:
From: LhelenB@AOL.COM
Sender: LUNG-ONC@LISTSERV.ACOR.ORG (LUNG-ONC: The Lung Cancer Online Support
Group)
Reply-to: LUNG-ONC@LISTSERV.ACOR.ORG (LUNG-ONC: The Lung Cancer Online
Support Group)
To: LUNG-ONC@LISTSERV.ACOR.ORG
Date: 97-10-21 14:41:05 EDT
Can't remembe who was talking about Hydrazine Sulfate but felt you all may
be interested in this. Helen B
In a message dated 97-10-21 01:36:46 EDT, you write:
>
> Thought you would all be interested in this article posted to Hem-
> Onc and CLL.
>
> Grannybarb
>
> - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
> GrannyBarb Lackritz, Leukemia survivor, email: lackritz@mvp.net
> List Manager CLL, email: CLL-request@listserv.acor.org
> List Manager HEM-ONC: hem-onc-request@listserv.acor.org
> http://www.acor.org/diseases/hematology/Leukemia/leukemia.html
> -----------------
>
> ---------- Forwarded message ----------
> Subj: Senate Subcommittee Counsel Validates Penthouse Magazine's
> Accusation That A Go
> Date: 97-10-20 16:07:04 EDT
> From: AOL News
>
> WASHINGTON--(BUSINESS WIRE)--Oct. 20, 1997--
>
> Chief Minority Counsel Says G.A.O. Conclusions About Hydrazine Sulfate
> Tests Were "Plainly Absurd" and "Extremely Misleading"
> Following leads developed in investigative reports in Penthouse
> magazine, the Chief Counsel for the Minority of the Permanent
> Subcommittee on Investigations of the U.S. Senate has sharply
> criticized the Government Accounting Office (G.A.O.) for issuing an
> "extremely misleading" report on studies to determine the
> effectiveness of hydrazine sulfate, an inexpensive cancer fighting
> drug.
> An investigation by the G.A.O. of tests conducted by the
> National Cancer Institute (N.C.I.) had been demanded by Penthouse as
> part of the magazine's long campaign to get a fair trial for
> hydrazine sulfate. Penthouse had alleged that for political purposes
> the N.C.I. deliberately sabotaged the human trials of hydrazine
> sulphate, and that the G.A.O. had ignored evidence that the tests
> were flawed.
> In a scathing letter to Marsha Lillie-Blanton, associate
director
> for Health Services Quality and Public Health Issues of the G.A.O.,
> minority counsel Jeffrey S. Robbins charged that the G.A.O.'s
> findings after investigating tests of the drug by the N.C.I. were
> themselves "plainly absurd."
> Robbin's seven-page letter denounced the G.A.O. for issuing a
> report with the title, "Contrary to Allegations, N.I.H. (National
> Institutes of Health) Hydrazine Sulfate Studies Were Not Flawed."
> Robbins says the G.A.O.'s own investigation of the studies was deeply
> flawed. The G.A.O. is the watchdog authority responsible for
> monitoring performance by government agencies.
> "The findings by Mr. Robbins fully validate a report in the
> September Penthouse charging that the G.A.O. is in collusion with
> the N.C.I. to suppress public knowledge of this exceptional drug,"
> said Bob Guccione, publisher of Penthouse. The report was called
> "The $200 Billion Scam--In the War Against Cancer, Our Government is
> the Enemy."
> Since the early 1980s Penthouse had urged valid government
> sponsored tests for hydrazine sulfate, but had uncovered evidence
> that when they finally took place, the tests were intentionally
> sabotaged by the N.C.I. Subsequently, the magazine reported, the
> G.A.O. accepted the N.C.I. test process despite considerable
> evidence that the studies conducted from 1989 to 1993 were purposely
> compromised.
> Joseph Gold, M.D., director of the Syracuse Cancer Research
> Institute and chief developer of hydrazine sulfate as a cancer
> therapy, had complained that the N.C.I. allowed patients in its
> tests of the drug to break protocol and use tranquilizers and other
> incompatible substances, effectively canceling out the beneficial
> effects of the drug, killing some patients and causing others to
> become much sicker.
> "Since the N.C.I. studies involved the administration of
> tranquilizers to virtually all patients concurrently with hydrazine
> sulfate, and since the precise allegation has been that use of the
> tranquilizers renders hydrazine sulfate ineffective, it is axiomatic
> that if they are ineffective, the N.C.I. studies are not merely
> flawed, but fundamentally flawed," said Mr. Robbins. "Yet the
> G.A.O. has pronounced conclusively that the N.C.I. studies' were
> not flawed,' while at the same time admitting that it has no idea
> whether or not the underlying allegation is true."
> According to his letter, when he first confronted the G.A.O.
> with his concerns, Mr. Robbins was told that "not many people read
> G.A.O. reports," he wrote in his letter to Ms. Lillie-Blanton. "I
> responded that I did not believe that was the case and that many
> people, including Members of Congress and their staffs, do rely on
> G.A.O. reports...and that the statement that not many people read a
> report is a very weak justification for false, misleading, or
> baseless information contained in a government publication."
> The Senate subcommittee letter has added significance because
> Penthouse and its parent company, General Media International, have
> issued a call for families of patients in the tests of hydrazine
> sulfate to participate in a class-action lawsuit under consideration
> against the N.C.I. "We have already received a sufficient number of
> potential plaintiffs to commence a class-action suit and are now
> considering where and when to file," according to Mr. Guccione, who
> is also Chairman and CEO of General Media.
> One of the strongest advocates of hydrazine sulfate was Kathy
> Keeton Guccione, Vice Chairman of General Media who believed the drug
> was instrumental in extending her life after she was discovered to
> have breast cancer in May, 1995 and was given six weeks to live. Ms.
> Keeton died in September of this year of complications following
> surgery to remove an intestinal blockage.
> "Kathy was aware that the Senate subcommittee was investigating
> the bizarre conclusions reached by the G.A.O. and she would have
> been extremely pleased that the cancer establishment and those who
> seem to accept its arrogant findings at face value are finally being
> called to task by a conscientious subcommittee counsel," said Mr.
> Guccione, her husband.
> Mr. Robbins said in his letter that the G.A.O. had never
> adequately addressed serious concerns about the studies of hydrazine
> sulfate raised by Dr. Gold. "The seriousness of (Gold's) points,
> and the obvious need to ensure that potential tools against cancer
> are evaluated in a rational way," require that the G.A.O. address
> Gold's questions "squarely, and not in an inapposite or conclusory
> fashion."
> "You have indicated that you believe that the G.A.O. report has
> problems warranting correction," Mr. Robbins wrote in his
> seven-page letter. He urged the agency to force the N.C.I. to be
> responsive to new questions about its testing in a manner that
> "inspired confidence."
> -0-
> For more information, a faxed copy of letter from Jeffrey Robbins
> to G.A.O., or for interviews with Bob Guccione or Dr. Joseph Gold,
> contact: Jackie Markham or Heather Krug at: 212-687-1765 or
> 212-702-6000 ext. 1901
> CONTACT:
> Jackie Markham/Heather Krug
> 212/687-1765
> 212/702-6000 ext. 1901
>
> To edit your profile, go to keyword NewsProfiles.
> For all of today's news, go to keyword News.
>
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
